The quarter was essentially in line, but not a beat. Liquidia reported $171.7 million of revenue and $0.74 diluted EPS, versus published expectations of approximately $171.9 million and $0.75, respectively—small misses on both headline measures.
| Metric | Q2 2026 | Q2 2025 | Expectation |
|---|---|---|---|
| Product sales, net | $170.4M (Product sales, net) | $6.5M (Product sales, net) | — |
| Total revenue | $171.7M (Income Statement) | $8.8M (Income Statement) | ~$171.9M |
| Net income | $74.7M (Income Statement) | $(41.6)M (Income Statement) | — |
| Diluted EPS | $0.74 (Income Statement) | $(0.49) (Income Statement) | ~$0.75 |
| Adjusted EBITDA | $96.3M (Reconciliation of Non-GAAP Financial Information) | — | — |
| Cash and equivalents | $284.2M (Balance Sheet) | $190.7M at December 31, 2025 (Balance Sheet) | — |
YUTREPIA has become a real commercial engine, but the growth was already the central expectation. Product sales reached $170.4 million, up from $6.5 million a year earlier, and the company posted its fourth consecutive profitable quarter. That confirms the commercial launch is scaling, but the result does not show a meaningful upside surprise against the roughly $172 million revenue bar.
Profitability improved dramatically despite heavier investment. Net income reached $74.7 million and adjusted EBITDA $96.3 million, while research and development rose 185% to $17.2 million and selling, general and administrative expense increased 48% to $57.4 million. The key takeaway is operating leverage: YUTREPIA's sales growth more than absorbed the higher commercial and L606 spending. (Income Statement)
The balance sheet provides more room to fund the next phase. Cash and equivalents rose to $284.2 million from $190.7 million at December 31, 2025, while stockholders' equity increased to $195.1 million from $44.7 million. That supports continued L606 development and commercialization without an immediate financing signal in this filing. (Balance Sheet)
The net read is a narrow miss, not a thesis break. The filing confirms strong YUTREPIA adoption, rising profitability, and progress toward Re-Spire enrollment, but it does not raise an outlook or deliver financial upside beyond what the market was already expecting. The remaining strategic uncertainty is whether L606 can broaden the growth story and how ongoing litigation could affect YUTREPIA's ability to remain on the market. (Corporate update; Risk factors)
Read the original 8-K on SEC EDGAR ↗